An immune-therapeutic salvage strategy for 'functional' high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study
Latest Information Update: 25 Jun 2024
At a glance
- Drugs Dexamethasone (Primary) ; Iberdomide (Primary) ; Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IBIS study
- 12 Aug 2021 New trial record